• Chimeron Bio and NCBID to develop Covid-19 vaccine pharmaceutical-technology
    June 01, 2020
    RNA therapeutics firm Chimeron Bio has collaborated with George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID) to develop a Covid-19 vaccine candidate.
PharmaSources Customer Service